NEWS

WIRES

OTHER

Over-the-Counter (OTC) Pain Reliever, Cobroxin, to be Sold in Walgreens

"As one of the largest and most well recognized pharmacy chains in North America, we are pleased that Walgreens has chosen to offer Cobroxin for sale in its drugstores throughout the United States," commented Frank Rizzo, President and CEO of XenaCare Holdings. "We look forward to working closely with Walgreens as we prepare for this launch and finalize our promotional strategy to support ongoing sales efforts by the retailer," he added.

Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. Cobroxin is currently available as an Advanced Oral Spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as an Advanced Topical Gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additional benefits to Cobroxin include:

• All Natural
• Non-Addictive
• Non-Narcotic
• Non-Opiate
• Long Lasting

XenaCare Holdings was granted a license by Nutra Pharma Corporation (OTCBB:NPHC), the biotechnology company that developed and currently manufactures Cobroxin, to market and distribute Cobroxin within the United States.

About XenaCare Holdings

XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin, for the treatment of moderate to severe (Stage 2) chronic pain, the Company's clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body's oxygen carrying capacities designed to support digestion. In addition, the company offers formulations for the lifestyle performance market, which consists of a sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet as well as pharmacies. The company was founded in 2001 and is based in Delray Beach, Florida.

http://www.XenaCareHoldings.com

http://www.Cobroxin.com

Cautionary Note Concerning Forward Looking Statements

Except for the historical and present factual information contained herein, the matters set forth in this document, including statements regarding our plans for specific advertising and marketing campaigns supporting Cobroxin are forward looking statement and subject to change. Investors are cautioned that these forward-looking statements are not guarantees of future performance. Actual events or results may differ from the Company's current plans. There are many risks, uncertainties and other factors that can prevent the achievement of our goals or cause results to differ from those expressed or implied by these forward-looking statements including, without limitation, the risks described in greater detail in filings made by the Company with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future events make it clear that any of the anticipated results expressed or implied herein will not be realized. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.

XenaCare Holdings
Frank Rizzo, 561-496-6676
frizzo@xenacare.com